Literature DB >> 16185589

[Euthanasia in patients with cancer and the continuous-care providers].

Carlos Camps Herrero1, Joaquín Gavilá Gregori, Javier Garde Noguera, Cristina Caballero Díaz, Vega Iranzo González-Cruz, Asunción Juárez Marroquí, Maria José Safont Aguilera, Ana Blasco Cordellat, Alfonso Berrocal Jaime, Maria Godes Sanz de Bremond.   

Abstract

During the clinical evolution of patients with cancer there are many occasions, or phases of the disease, when there are no specific treatments and, as such, we need to provide maximum comfort following appropriate symptom control; in this stage it is fundamental to respect personal autonomy together with the option to reject futile treatment. With appropriate control of symptoms it is possible to reach the stage where the majority of the patients do not continue to suffer. Continuous-care providers for cancer patients are those who are responsible for providing help to resolve these situations. In palliative medicine there are highly-efficacious procedures to the help in these last hours. Sedation is applied when it is impossible to control symptoms by other means. With appropriate Carer cover, it is not necessary to introduce laws on assisted suicide and/or active voluntary euthanasia, neither because of the magnitude of demand, nor because of the difficulties in achieving appropriate control of symptoms.

Entities:  

Mesh:

Year:  2005        PMID: 16185589     DOI: 10.1007/bf02710266

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  19 in total

1.  [The end of life: could it be comfortable?].

Authors:  J Sanz Ortiz
Journal:  Med Clin (Barc)       Date:  2001-02-10       Impact factor: 1.725

2.  Australia's Northern Territory: the first jurisdiction to legislate voluntary euthanasia, and the first to repeal it.

Authors:  A L Plattner
Journal:  DePaul J Health Care Law       Date:  1997

3.  Death and dignity. A case of individualized decision making.

Authors:  T E Quill
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245

4.  A national survey of physician-assisted suicide and euthanasia in the United States.

Authors:  D E Meier; C A Emmons; S Wallenstein; T Quill; R S Morrison; C K Cassel
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

5.  Stability of attitudes regarding physician-assisted suicide and euthanasia among oncology patients, physicians, and the general public.

Authors:  J Wolfe; D L Fairclough; B R Clarridge; E R Daniels; E J Emanuel
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

6.  Attitudes of terminally ill cancer patients about euthanasia and assisted suicide: predominance of psychosocial determinants and beliefs over symptom distress and subsequent survival.

Authors:  Maria E Suarez-Almazor; Catherine Newman; John Hanson; Eduardo Bruera
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

7.  The double effect of pain medication: separating myth from reality.

Authors:  S A Fohr
Journal:  J Palliat Med       Date:  1998       Impact factor: 2.947

8.  Will to live in the terminally ill.

Authors:  H M Chochinov; D Tataryn; J J Clinch; D Dudgeon
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

9.  [Attitudes towards active euthanasia and its legislation in Spain].

Authors:  C Vega Vega; V Moya Pueyo
Journal:  Med Clin (Barc)       Date:  1992-04-11       Impact factor: 1.725

10.  The incidence and characteristics of end-of-life decisions by GPs in Belgium.

Authors:  Johan Bilsen; Robert Vander Stichele; Freddy Mortier; Jan Bernheim; Luc Deliens
Journal:  Fam Pract       Date:  2004-06       Impact factor: 2.267

View more
  2 in total

1.  [The end of the last disease].

Authors:  Jaime Sanz Ortiz
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

2.  Professional burnout among Spanish medical oncologists.

Authors:  C Camps; Y Escobar; E Esteban; J A Almenárez; B Moreno Jiménez; M Gálvez Herrer; P Arranz; P T Sánchez
Journal:  Clin Transl Oncol       Date:  2009-02       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.